Cargando…
AR activates YAP/TAZ differentially in prostate cancer
The Hippo signalling pathway is a master regulator of cell growth, proliferation, and cancer. The transcriptional coregulators of the Hippo pathway, YAP and TAZ, are central in various cancers. However, how YAP and TAZ get activated in most types of cancers is not well understood. Here, we show that...
Autores principales: | Salem, Omar, Jia, Siyang, Qian, Bin-Zhi, Hansen, Carsten Gram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310930/ https://www.ncbi.nlm.nih.gov/pubmed/37385752 http://dx.doi.org/10.26508/lsa.202201620 |
Ejemplares similares
-
YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations
por: Cunningham, Richard, et al.
Publicado: (2023) -
PERCC1, a new member of the Yap/TAZ/FAM181 transcriptional co-regulator family
por: Sanchez-Pulido, Luis, et al.
Publicado: (2022) -
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
por: Cunningham, Richard, et al.
Publicado: (2022) -
Hippo-Yap/Taz signalling in zebrafish regeneration
por: Riley, Susanna E., et al.
Publicado: (2022) -
TAZ and YAP are frequently activated oncoproteins in sarcomas
por: Fullenkamp, Colleen A., et al.
Publicado: (2016)